**Core Concept**
The initiation of β-blocker therapy in patients with congestive heart failure (CHF) is a critical step in managing the condition. This involves understanding the pathophysiological basis of CHF and how β-blockers exert their beneficial effects.

**Why the Correct Answer is Right**
β-blockers, such as carvedilol and metoprolol succinate, are used in CHF to reduce morbidity and mortality. They work by reducing the sympathetic tone on the heart, which in turn decreases the heart rate and contractility. This leads to a decrease in oxygen demand of the heart, reducing the workload on the heart. Additionally, β-blockers have vasodilatory effects, which further decrease the afterload on the heart. The reduction in heart rate and contractility also leads to a decrease in the production of pro-inflammatory cytokines and a reduction in the expression of genes involved in fibrosis.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because β-blockers should not be initiated in patients with acute heart failure or decompensated heart failure. They should only be started in stable patients with chronic heart failure.
**Option B:** This option is incorrect because the initial dose of β-blocker should be low and titrated upward over time, rather than starting at a high dose. This allows the heart to adapt to the decreased sympathetic tone and reduces the risk of adverse effects.
**Option C:** This option is incorrect because β-blockers are not contraindicated in patients with asthma or chronic obstructive pulmonary disease (COPD). However, caution should be exercised when initiating β-blockers in these patients, as they may precipitate bronchospasm.

**Clinical Pearl / High-Yield Fact**
When initiating β-blocker therapy in CHF, it is essential to start with a low dose and titrate upward over time to avoid adverse effects. This approach allows the heart to adapt to the decreased sympathetic tone and reduces the risk of exacerbating the condition.

**Correct Answer:** A.